University Hospital of Freiburg
Welcome,         Profile    Billing    Logout  
 17 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Engelhardt, Monika
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
MYRIAM, NCT03308474: Myeloma Registry Platform

Recruiting
N/A
2200
Europe
Routine care as per site standard.
iOMEDICO AG, Deutsche Studiengruppe Multiples Myelom (DSMM)
Multiple Myeloma
12/26
12/28
Wäsch, Ralph
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
INITIAL-1, NCT03460522 / 2016-004836-39: Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Recruiting
2
65
Europe
Inotuzumab ozogamicin
Nicola Goekbuget, Pfizer Pharma GmbH
Precursor Cell Lymphoblastic Leukemia
06/25
12/25
Niemeyer, Charlotte
HIT-HGG-2013, NCT03243461 / 2013-004187-56: International Cooperative Phase III Trial of the HIT-HGG Study Group

Recruiting
3
167
Europe
Temozolomide + Valproic Acid
University of Göttingen, Deutsche Kinderkrebsstiftung, Hannover Medical School
Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma, Gliomatosis Cerebri
12/23
12/23
AIEOP-BFM ALL 2017, NCT03643276 / 2016-001935-12: Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia -

Recruiting
3
5000
Europe, RoW
Blinatumomab, Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, Etoposide, Fludarabine Phosphate, Ifosfamide, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Tioguanin, Vincristine, Vindesine, Erwinase
Martin Schrappe, Deutsche Krebshilfe e.V., Bonn (Germany)
Acute Lymphoblastic Leukemia, Pediatric
07/28
07/28
FORUM, NCT01949129 / 2012-003032-22: Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Recruiting
2/3
1800
Europe, Canada, RoW
VP16, Etoposide, TBI, Thiotepa, Thio, Treosulfan, Treo, Fludarabine, Flu, Busulfan, Bu, ATG Thymoglobulin, ATG Thymo, Cyclophosphamide, Cy, Grafalon, Anti-human T-lymphocyte immunoglobulin
St. Anna Kinderkrebsforschung, ALL SCTped Forum, European Society for Blood and Marrow Transplantation, ALL-BFM Study Group, Assistance Publique - Hôpitaux de Paris, Dutch Childhood Oncology Group, Swiss Pediatric Oncology Group, Australian & New Zealand Children's Haematology/Oncology Group
Acute Lymphoblastic Leukaemia
06/25
04/30
EWOG MDS 2006, NCT00662090: Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood

Active, not recruiting
N/A
260
Europe
University Hospital Freiburg
Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia
12/23
12/24
ESCORT-HU Extension, NCT04707235: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study

Active, not recruiting
N/A
2093
Europe, RoW
Hydroxycarbamide, Siklos, Hydroxyurea
Theravia, International Clinical Trials Association
Sickle Cell Disease
08/25
08/25
Fuhrer, Hannah
DON´T-PERISH, NCT04063982: Diagnosis-related Outcomes in NeurocriTical Care: Prognostic Estimate by Health-care Providers Versus Risk Scores in Intracerebral and Subarachnoid Hemorrhage

Recruiting
N/A
1000
Europe
none, only assessment at different time points
University of Leipzig, German Society of Neurocritical Care
Intracerebral Hemorrhage, Subarachnoid Hemorrhage
12/25
12/25

Download Options